Home / Market News / $STAA
benzinga Corporate Catalyst Impact 55/100 ● negative

Wedbush Reiterates Outperform on Staar Surgical, Maintains $40 Price Target

Jul 16, 2026, 3:15 PM UTC · Primary ticker $STAA

This filing discloses that Wedbush analyst Michael Piccolo has reiterated an 'Outperform' rating and maintained a $40 price target for Staar Surgical (STAA). This indicates continued analyst confidence in the company's prospects, which could provide some positive sentiment for investors.

Wedbush analyst Michael Piccolo reiterated an 'Outperform' rating and maintained a $40 price target for Staar Surgical (STAA). This action signals that the analyst's view on the company's fundamentals and future performance remains unchanged and positive. For traders, this provides a reaffirmation of a bullish stance, potentially reinforcing existing long positions or attracting new buyers. While not a new catalyst, it can contribute to short-term positive sentiment and stability for STAA, as it suggests no immediate negative surprises are anticipated by this analyst. The long-term implication is a continued belief in the company's growth trajectory, though the impact is moderate as it's a reiteration rather than an upgrade or new coverage.

$STAA positive Analyst rating reiterated
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.